Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Patent
1997-09-22
2000-08-22
Stucker, Jeffrey
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
435 792, 435 793, 435 794, 435 795, 435331, 436518, 436532, 530323, 530326, 530327, 530328, 5303881, 5303891, 530387, G01N 3353
Patent
active
061070475
DESCRIPTION:
BRIEF SUMMARY
This application is a national stage entry of EP96/01228.
The present invention relates to the assaying of collagen or other protein degradation products and materials useful therefor.
COLLAGENS AND DISORDERS OF COLLAGEN METABOLISM
Osteoporosis is the most common bone disease in humans. Primary osteoporosis, accompanied by increased susceptibility to fractures, results from a progressive reduction in skeletal bone mass. It is estimated to affect 15-20 million individuals in the USA alone. Its basis is an age-dependant imbalance in bone remodelling, i.e. in the rates of formation and resorption of bone tissue.
In the USA about 1.2 million osteoporosis-related fractures occur in the elderly each year including about 538,000 compression fractures of the spine, about 227,000 hip fractures and a substantial number of early fractured peripheral bones. Between 12 and 20% of the hip fractures are fatal because they cause severe trauma and bleeding, and half of the surviving patients require nursing home care. Total costs from osteoporosis-related injuries now amount to at least $10 billion annually in the USA (Riggs, New England Journal of Medicine, 327:620-627 (1992)).
Osteoporosis is most common in postmenopausal women who, on average, lose 15% of their bone mass in the 10 years after menopause. This disease also occurs in men as they get older and in young amenorrheic women athletes. Despite the major, and growing, social and economic consequences of osteoporosis, the availability of reliable assays for measuring bone resorption rates in patients or in healthy subjects is very limited. Other disorders entailing (and correlated with) abnormalities in collagen metabolism include Paget's disease, Marfan's syndrome, osteogenesis imperfecta, neoplastic growth in collagenous tissue, dwarfism, rheumatoid arthritis, osteoarthritis and vasculitis syndrome.
Three known classes of human collagen have been described to date. The Class I collagens, subdivided into types I, II, III, V, and XI, are known to form fibrils. The amino-acid sequence of type I-III (to the extent it has been elucidated) is given in Appendix A of WO95/08115.
Collagen type I accounts for more than 90% of the organic matrix of bone. Therefore, in principle, it is possible to estimate the rate of bone resorption by monitoring the degradation of collagen type I. Likewise, a number of other disease states involving connective tissue can be monitored by determining the degradation of collagen. Examples are collagen type II degradation associated with rheumatoid arthritis and osteoarthritis and collagen type III degradation in vasculitis syndrome.
Amino acid sequences of human type III collagen, human pro .alpha.1(II) collagen, and the entire prepro .alpha.1(III) chain of human type III collagen and corresponding cDNA clones have been investigated and determined by several groups of researchers; see Loil et al., Nucleic Acid Research 12:9383-9394 (1984): Sangiorgi et al., Nucleic Acids Research, 13:2207-2225 (1985); Baldwin et al., Biochem J., 262:521-528 (1989); and Ala-Kokko et al., Biochem. J., 260:509-516 (1989).
Type I, II, and III collagens are all formed in the organism as procollagen molecules, comprising N-terminal and C-terminal propeptide sequences, which are attached to the core collagen molecules. After removal of the propeptides, which occurs naturally in vivo during collagen synthesis, the remaining core of the collagen molecules consists largely of a triple-helical domain having terminal telopeptide sequences which are non-triple-helical. These telopeptide sequences have an important function as sites of intermolecular cross-linking of collagen fibrils extracellularly. The alpha-helical region also includes crosslinkable sites.
Intermolecular cross-links provide collagen fibrils with biomechanical stability. The formation of these cross-links is initiated by modification of lysine and hydroxylysine residues to the corresponding aldehydes. Several of these residues located on adjacent chains of collagen will spontaneously form different in
REFERENCES:
patent: 3600132 (1971-08-01), Goverde
patent: 4312853 (1982-01-01), Timpl
patent: 4504587 (1985-03-01), Timpl et al.
patent: 4628027 (1986-12-01), Gay
patent: 4778768 (1988-10-01), Heinegard et al.
patent: 4973666 (1990-11-01), Eyre
patent: 5001225 (1991-03-01), Taylor
patent: 5140103 (1992-08-01), Eyre
patent: 5300434 (1994-04-01), Eyre
patent: 5320970 (1994-06-01), Eyre
patent: 5455179 (1995-10-01), Eyre
patent: 5472884 (1995-12-01), Eyre
patent: 5473052 (1995-12-01), Eyre
patent: 5532169 (1996-07-01), Eyre
patent: 5576189 (1996-11-01), Eyre
patent: 5607862 (1997-03-01), Eyre
patent: 5641837 (1997-06-01), Eyre
patent: 5652112 (1997-07-01), Eyre
patent: 5656439 (1997-08-01), Eyre
patent: 5679583 (1997-10-01), Brocks et al.
patent: 5763272 (1998-06-01), Naser et al.
patent: 5821065 (1998-10-01), Naser et al.
patent: 5834221 (1998-10-01), Eyre
patent: 5912131 (1999-06-01), Eyre
patent: 5939274 (1999-08-01), Eyre
patent: 5962639 (1999-10-01), Eyre
International Search Report dated Feb. 15, 1995 of Int'l Appl. No. PCT/DK94/00348.
Ala-Kokko et al., 1989, "Structure of cDNA clones coding for the entire prepro.alpha.1 (III) chain of human type III procollagen", Biochem. J. 260:509-516.
Ala-Kokko et al., 1990, "Single base mutation in the type II procollagen gene (COL2A1) as a cause of primary osteoarthritis associated with a mild chondrodysplasia", Proc. Natl. Acad. Sci. 87:6565-6568.
Baldwin et al., 1989, "Structure of CDNA clones coding for human type II procollagen", Biochem. J. 262:521-528.
Beardsworth et al., 1990, "Changes with age in the urinary excretion of lysyl- and hydroxylysylpridinoline, two new markers of bone collagen turnover", J. Bone Miner. Res. 5:671-676.
Bernard et al., 1983, "Nucleotide Sequences of Complementary Deoxyribonucleic Acids for the Pro.alpha.1 Chain of Human Type I Procollagen. Statistical Evaluation of Structures That Are Conserved during Evolution", Biochemistry 22:5213-5223.
Black et al., 1988, "Quantitative analysis of the pyridinium crosslinks of collagen in urine using ion-paired reversed-phase high-performance liquid chromatography", Ana. Biochem. 169:197-203.
Black et al., 1989, "Urinary excretion of the hydroxypyridinium cross links of collagen in patients with rheumatoid arthritis", Annals of the Rheumatic Diseases 48:641-644.
Bonde et al., 1994, "Immunoassay for Quantifying Type 1 Collagen Degradation Products in Urine Evaluated", Clin. Chem. 40(11):2022-2025.
Bonde et al., 1995, "Measurement of Bone Degradation Products in Serum Using Antibodies Reactive with an 8 Amino Acid Sequence of the C-Telopeptides of Type I Collagen", J. of Bone and Min. Res. 10:1-Abstract S481.
Brennan et al., 1993, "Spontaneous degradation of polypeptides at aspartyl and asparaginyl residues: Effects of the solvent dielectric", Protein Science 2:331-338.
Capecchi et al., "Critical examination of a method for the analysis of .alpha. and .omega. linkages in peptides containing aspartic acid and glutamic acid", J. Org. Chem. 48:2014-2021.
Christiansen et al., "Prediction of future fracture risk", eds, Proceedings 1993. Fourth International Symposium on Osteoporosis, Hong Kong. Osteopress Aps 1993; pp. 52-54.
Chu et al., 1984, "Human pro.alpha.1(I) collagen gene structure reveals evolutionary conservation of a pattern of itrons and exons", Nature 310:337-340.
Click et al., 1970, "Isolation and Characterization of the Cyanogen Bromide Peptides from the .alpha.1 and .alpha.2 Chains of Human Skin Collagen", Biochemistry 9:4699-4706.
de Wet et al., 1987, "Organization of the Human Pro-.alpha.2(I) Collagen Gene", J. Biol. Chem. 262:16032-16036.
del Pozo et al., 1986, "Binding of 1-anilinoaphthalene-8-sulfonic acid to type I collagen" Int. J. Pept. Protein Res. 28:173-178.
Delmas et al., 1986, "Serum Bone GLA-Protein in Growth Hormone Deficient Children", J. Bone Min. Res. 1:333-337.
Delmas, P.D., 1990, "Biochemical markers of bone turnover for the clinical assessment of metabolic bone disease", Metabolic Bone Dis. 19:1-18.
Dickson et al.,
Bonde Martin
Fledelius Christian
Qvist Per
Osteometer Biotech A/S
Stucker Jeffrey
LandOfFree
Assaying protein fragments in body fluids does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Assaying protein fragments in body fluids, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Assaying protein fragments in body fluids will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-579092